Duality of Interest. M.M.Y.L. has received research grants through his institution, the University of Glasgow, from AstraZeneca, Boehringer Ingelheim, and Roche Diagnostics and is a member of a Trial Steering Committee for Cytokinetics and a Clinical Endpoints Committee for Bayer. N.G. has received speaker honoraria from Novo Nordisk (nonpromotional activity) and Boehringer Ingelheim within the past 3 years. A.M. reports consulting/speaker honoraria from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Janssen, Sanofi, Lupin, US Vitamins, Cipla, and Glenmark. M.K.R. reports consulting honoraria from Eli Lilly. H.C.G. holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, AstraZeneca, Novo Nordisk, Hanmi, and Merck; continuing education grants from Eli Lilly, Abbott, Sanofi, Novo Nordisk, and Boehringer Ingelheim; honoraria for speaking from AstraZeneca, Eli Lilly, Novo Nordisk, DKSH, Zuellig, Sanofi, Carbon Brand, and Jiangsu Hanson; and consulting fees from Abbott, Bayer, Eli Lilly, Novo Nordisk, Pfizer, Sanofi, Kowa, and Hanmi. D.K.M. has received honoraria for trial leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, CSL Behring, Eidos, and NewAmsterdam and honoraria for consultancy from Lilly USA, Boehringer Ingelheim, Novo Nordisk, Applied Therapeutics, Bayer, Altimmune, Intercept, Alnylam, Amgen, and Neurotronics. N.S. reports consulting/speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi and grants from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. No other potential conflicts of interest relevant to this article were reported.
PubMed
